November is National Epilepsy Awareness Month – a milestone that allows us to pause and reflect on both the progress the community has made for people living with this condition and their continued unmet needs. This time of reflection is especially important for people diagnosed with rare forms of epilepsy, as well as their families and caregivers, who are continuing to search for improved therapeutic outcomes.

Recently, Mat Davis, PhD, vice president and head of data science, presented at the 2023 STAT Summit where he shared a key moment in his career when he learned the necessity of breaking down silos to fully embrace quantitative experts across the three avenues of drug development.

As World Heart Day approaches, we are reminded of people who live with complex sleep disorders and how we can adequately address their unique needs. Learn more about the importance of thinking holistically about narcolepsy and idiopathic hypersomnia patients’ health from Jazz’s Dr. Kelvin Tan and Dr. Logan Schneider of the Stanford University School of Medicine.

As a leader in sleep medicine, Jazz’s nearly 20-year leadership has been built around tackling rare sleep conditions, all while centering on and giving a voice to the patient and caregiver experiences, such as those living with idiopathic hypersomnia. Read more about our plans to expand and spotlight the I Have IH awareness campaign at SLEEP 2023. 

For nearly 20 years, Jazz Pharmaceuticals has been a leader in sleep medicine. At SLEEP 2023, we reflect on our key learnings from the past two decades and reaffirm our longstanding commitment to the sleep community.

As both ASCO and SLEEP kick off this weekend, we are excited to meet with thought leaders and advocates across the oncology and sleep communities. By applying our pioneering approach and deep expertise in sleep disorders and oncology, we are working hard to advance industry-leading research and development so we can deliver new potential therapies to help even more patients.